This centre for drug-design aims at combating some of the most serious diseases afflicting humanity such as tuberculosis, malaria, leishmaniasis, sleeping sickness and Chagas’ disease. The centre will bring together leading medicinal/combinatorial chemistry, computational chemistry and structural biology groups in a multi-disciplinarian effort. The main drug targets will initially be mostly proteases. There is mounting evidence that these enzymes play crucial roles in e g the metabolism, replication, survival and pathology of parasites. Proteases have been targets also for other successful drug-discovery programmes in the past.
The centre will deliver PhDs trained in computational chemistry, structural biology and medicinal chemistry that are tailor-made for the Swedish pharmaceutical industry as well as for academia. The centre will also deliver high-quality science and potential lead compounds for further development by the pharmaceutical industry into agents against disease.